Eli Lilly (LLY) is acquiring CrossBridge Bio for $300 million to enhance its oncology pipeline. The deal includes CBB-120, a dual-payload antibody-drug conjugate targeting solid tumours. This technology uses two mechanisms to reduce resistance. Lilly expects to file for FDA trials in 2026, sending shares higher.